Current landscape and support for practical initiation of oncological prehabilitation translatable to thyroid cancer: A position paper.

Autor:	Jack S; Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, University Road, Southampton, SO17 1BJ, UK., Andritsch E; Clinical Department of Oncology, University Medical Centre of Internal Medicine, Medical University of Graz, Auenbruggerpl. 2, 8036, Graz, Austria., Joaquim A; ONCOMOVE®, Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), 4410-406, Vila Nova de Gaia, Portugal., Kreissl MC; Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Otto von Guericke University, Universitatsplätz 2, 39106, Magdeburg, Germany., Locati L; Department of Internal Medicine and Therapeutics, University of Pavia, S. da Nuova, 65, 27100, Pavia, PV, Italy.; Medical Oncology Unit, IRCCS ICS, Maugeri, Via Salvatore Maugeri, 10, 27100 Pavia PV, Italy., Netea-Maier RT; Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, Geert Grooteplein Zuid 28, 6525, GA, Nijmegen, the Netherlands., Reverter JL; Endocrinology and Nutrition Department, Germans Trias i Pujol University Hospital, Universidad Autónoma de Barcelona, Placa Civica, 08193, Bellaterra, Barcelona, Spain., Elisei R; Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Lungarno Antonio Pacinotti, 43, 56126, Pisa, PI, Italy.
Jazyk:	angličtina
Zdroj:	Heliyon [Heliyon] 2024 May 11; Vol. 10 (10), pp. e30723. Date of Electronic Publication: 2024 May 11 (Print Publication: 2024).
DOI:	10.1016/j.heliyon.2024.e30723
Abstrakt:	Despite a growing body of evidence for the effectiveness of prehabilitation, the uptake of prehabilitation in Europe remains low. Contributing factors range from limited awareness and understanding of prehabilitation to a lack of supporting infrastructure and reimbursement challenges. In this position paper, the authors propose a new comprehensive definition of prehabilitation and identify differentiated thyroid cancer as a type of cancer particularly well-suited for prehabilitation. To support clinicians with the implementation of prehabilitation programs in their clinics, the authors discuss the following practical solutions: a) find the most appropriate prehabilitation program for each patient; b) raise awareness among peers; c) develop evidence to demonstrate the effectiveness of prehabilitation; d) expand the interdisciplinary team; e) expand your network and make use of existing assets; f) utilize learnings from the COVID-19 pandemic. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rossella Elisei reports financial support was provided by 10.13039/501100003769Eisai Europe Ltd. Rossella Elisei reports a relationship with Eisai Inc that includes: consulting or advisory. Rossella Elisei reports a relationship with Ipsen that includes: consulting or advisory. Rossella Elisei reports a relationship with Bayer that includes: consulting or advisory. Rossella Elisei reports a relationship with Lilly that includes: consulting or advisory. Rossella Elisei reports a relationship with Roche that includes: consulting or advisory. J.L. Reverter reports a relationship with Eisai Inc that includes: consulting or advisory. R.T. Netea-Maier reports a relationship with Eisai Inc that includes: consulting or advisory. L. Locati reports a relationship with 10.13039/501100003769Eisai Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. L. Locati reports a relationship with MSD that includes: consulting or advisory, funding grants, and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004334Merck Serono that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with Lilly that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004339Sanofi that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with Sun Pharmaceutical Industries Ltd that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/501100014382Ipsen that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004326Bayer that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004337Roche that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with Instituto Gentili Srl that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with New Bridge that includes: consulting or advisory and speaking and lecture fees. E. Andritsch reports a relationship with Eisai Inc that includes: consulting or advisory. A. Joaquim reports a relationship with Bristol Myers Squibb that includes: consulting or advisory. A. Joaquim reports a relationship with 10.13039/501100003769Eisai Inc that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with 10.13039/100004334Merck that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with MSD that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with Novartis that includes: consulting or advisory. A. Joaquim reports a relationship with 10.13039/100004319Pfizer that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with Roche that includes: consulting or advisory. A. Joaquim reports a relationship with Daiichi Sankyo Inc that includes: speaking and lecture fees. A. Joaquim reports a relationship with Gillead that includes: speaking and lecture fees. A. Joaquim reports a relationship with 10.13039/100004330GlaxoSmithKline Inc that includes: speaking and lecture fees. A. Joaquim reports a relationship with Lilly that includes: speaking and lecture fees. A. Joaquim reports a relationship with 10.13039/501100006484Vifor Pharma that includes: speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/100004326Bayer Healthcare that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/501100003769Eisai Inc that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/100010544Exelixis that includes: consulting or advisory and funding grants. M.C. Kreissl reports a relationship with Factfield that includes: consulting or advisory. M.C. Kreissl reports a relationship with 10.13039/100004313General Electric that includes: consulting or advisory, funding grants, and speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/501100014382Ipsen that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with Liam GmbH that includes: consulting or advisory. M.C. Kreissl reports a relationship with Lilly that includes: consulting or advisory. M.C. Kreissl reports a relationship with 10.13039/100004336Novartis that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with Onkowissen Gmbh that includes: consulting or advisory. M.C. Kreissl reports a relationship with Pfizer that includes: consulting or advisory. M.C. Kreissl reports a relationship with Roche that includes: consulting or advisory. M.C. Kreissl reports a relationship with 10.13039/100013995Sanofi Genzyme that includes: consulting or advisory, funding grants, and speaking and lecture fees. M.C. Kreissl reports a relationship with Sirtex that includes: consulting or advisory, funding grants, and speaking and lecture fees. M.C. Kreissl reports a relationship with Takeda that includes: consulting or advisory. M.C. Kreissl reports a relationship with Thieme Publishing that includes: consulting or advisory. M.C. Kreissl reports a relationship with ITM that includes: funding grants and speaking and lecture fees. M.C. Kreissl reports a relationship with Tanaka that includes: speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/501100004830Siemens that includes: speaking and lecture fees. M.C. Kreissl reports a relationship with Curium that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu